Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non‐respiratory infections in common variable immune deficiency

Abstract

Overall, these data support the use of standard-dose 400 mg/kg intravenous immunoglobulin therapy, despite the high cost, to raise trough IgG levels to 5-7 g/l, but underlines that some categories of infectious events (non-respiratory, upper respiratory) may need parallel surgical or pharmacological approaches to be optimally prevented or treated.